Return-Path: <r34g3@hotmail.com>
Delivered-To: em-ca-bait@em.ca
Received: (qmail 6599 invoked by uid 115); 13 Dec 2004 14:16:46 -0000
Received: from r34g3@hotmail.com by churchill by uid 64011 with qmail-scanner-1.22 
 (clamdscan: 0.75-1. spamassassin: 2.63.  Clear:RC:0(222.134.6.205):. 
 Processed in 2.348799 secs); 13 Dec 2004 14:16:46 -0000
Received: from unknown (HELO earthlink.net) (222.134.6.205)
  by churchill.factcomp.com with SMTP; 13 Dec 2004 14:16:43 -0000
Received: from hotmail.com (mx1.hotmail.com [64.4.50.50])
	by earthlink.net with esmtp
	id D716054B16 for <bait@em.ca>; Mon, 13 Dec 2004 07:29:34 -0800
Reply-To: leebieLuies@hotmail.com
From: "Adapter E. Scrolls" <r34g3@hotmail.com>
To: Bait <bait@em.ca>
Subject: RE:MAKE SURE TO GET IN modem
Date: Mon, 13 Dec 2004 07:29:34 -0800
Message-ID: <111101c4e128$eac2842b$b6b37a0c@hotmail.com>
MIME-Version: 1.0
Content-Type: text/html
Content-Transfer-Encoding: quoted-printable
X-Priority: 3 (Normal)
X-MSMail-Priority: Normal
X-Mailer: Microsoft Outlook, Build 10.0.2627
Importance: Normal
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2800.1165
X-AntiVirus: OK! AntiVir MailGate Version 2.0.1; AVE: 6.15.0.0; VDF: 6.15.0.6

<html>
<head>
<title>Untitled Document</title>
<meta http-equiv=3d"Content-Type" content=3d"text/html; charset=3diso-885=
9-1">
</head>

<body>
<font color=3d"#0000FF" size=3d"3">INVESTMENT ALERT&#8230; </font><font s=
ize=3d"3"><br>
EMERGING BIOTECH COMPANY SOON TO RELEASE GROUND BREAKING MEDICAL DEVICE</=
font>=20
<p><font size=3d"2">In Vivo Medical Diagnostics, Inc <font color=3d"#FF00=
00">(Stock=20
  Symbol OTC: IVVO)</font> is finalizing its first ground-breaking portab=
le medical=20
  device, the Prothrombin Time Monitor, that measures changes in the magn=
etic=20
  fields of blood on a molecular level=2e This is critical for patients u=
ndergoing=20
  anticoagulation therapy after heart attacks and strokes=2e This measure=
ment is=20
  now portable and is used in real time to achieve optimal medication lev=
els,=20
  which is essential for successful treatment=2e IVVO has recently announ=
ced their=20
  joint effort with Inverness Medical Innovations a leading manufacturer =
and marketer=20
  of rapid diagnostic products in order to complete development of the Pr=
othrombin=20
  Time Monitor for its clinical trials=2e Prothrombin Testing is a massiv=
e market=20
  and continues to grow with projections in excess of $150 million in 200=
5 and=20
  over $500 million by 2010=2e IVVO is poised to capitalize on this signi=
ficant=20
  opportunity=2e Don&#8217;t miss out on the near term upside potential i=
n IVVO!=20
  </font><br>
  <br>
  <font color=3d"#0000FF" size=3d"3">INVESTMENT ANAYSIS </font></p>
<p><font size=3d"3">In Vivo Medical Diagnostics, Inc=2e (<font color=3d"#=
FF0000">Stock=20
  Symbol OTC: IVVO</font>)<br>
  Short-Term Target: $3=2e00<br>
  12-Month Target: $5=2e00<br>
  Recommendations: Very Strong Buy<br>
  Long Term Outlook: Excellent </font></p>
<p><font size=3d"2">Heart disease is the most common cause of death and c=
ardiovascular=20
  disease affects over 60 million people worldwide=2e The largest area of=
 growth=20
  in the Health Care Sector is in Patient Management=2e This growth is ca=
used by=20
  patients with chronic conditions, who are forced to make frequent and c=
ostly=20
  hospital visits to monitor their condition=2e </font></p>
<p><font size=3d"2">In Vivo Medical Diagnostics utilizes the Hall effect,=
 which=20
  is a well-known physics phenomenon that can be used to measure changes =
in magnetic=20
  fields at the molecular level=2e IVVO has taken this proven science and=
 has used=20
  it for imaging purposes which is applied to many different applications=
, including=20
  the cardiovascular and diabetes markets =2e</font></p>
<p><font size=3d"2">IVVO is a well-established company that has been oper=
ating for=20
  over eight years=2e IVVO currently has two additional products in their=
 2nd clinical=20
  trials, a pregnancy labor monitor and a fetal heart rate monitor, along=
 with=20
  12 Patents that will allow them to extend their technology to other eme=
rging=20
  medical solutions=2e IVVO is currently profitable with additional royal=
ty income=20
  beginning in 2005=2e IVVO has sufficient funds on hand to take them wel=
l into=20
  2006=2e </font></p>
<p><font size=3d"1">Information within this email contains &quot;forward =
looking=20
  statements&quot; within the meaning of Section 27A of the Securities Ac=
t of=20
  1933 and Section 21B of the Securities Exchange Act of 1934=2e Any stat=
ements=20
  that express or involve discussions with respect to predictions, goals,=
 expectations,=20
  beliefs, plans, projections, objectives, assumptions or future events o=
r performance=20
  are not statements of historical fact and may be &quot;forward looking =
statements=2e&#8221;=20
  Please be advised that nothing within this email shall constitute a sol=
icitation=20
  or an offer to buy or sell any security mentioned herein=2e This newsle=
tter is=20
  neither a registered investment advisor nor affiliated with any broker =
or dealer=2e=20
  This newsletter is not affiliated with In Vivo Medical Diagnostics, Inc=
 in any=20
  way=2e This newsletter was produced and distributed by a independent th=
ird party=2e=20
  All statements made are our express opinion only and should be treated =
as such=2e=20
  We may own, buy and sell any securities mentioned at any time=2e This r=
eport includes=20
  forward-looking statements within the meaning of The Private Securities=
 Litigation=20
  Reform Act of 1995=2e These statements may include terms as &quot;expec=
t&quot;,=20
  &quot;believe&quot;, &quot;may&quot;, &quot;will&quot;, &quot;move&quot=
;,&quot;undervalued&quot;=20
  and &quot;intend&quot; or similar terms=2e PLEASE DO YOUR OWN DUE DILIG=
ENCE BEFORE=20
  INVESTING IN ANY PROFILED COMPANY=2e You may lose money from investing =
in Penny=20
  Stocks=2e</font><br>
</p>
</body>
</html>


